Hyperglycemia in the critically ill

Nutrition in Clinical Care

Volumn 8, Issue 2, 2005, Pages 93-101

  Digman, Colleen ^a   Borto, Dara ^a   Nasraway Jr , Stanley A ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Glucose monitoring; Hyperglycemia; Intensive insulin

Indexed keywords

CELL FUNCTION; CRITICAL ILLNESS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMMUNOCOMPETENT CELL; METABOLIC ACTIVATION; MITOCHONDRIAL RESPIRATION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; POPULATION RESEARCH; REVIEW; TREATMENT OUTCOME; INTENSIVE CARE UNIT; METABOLISM; NUTRITIONAL SUPPORT;

ANTIDIABETIC AGENT; INSULIN;

BLOOD GLUCOSE; CRITICAL ILLNESS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTENSIVE CARE UNITS; NUTRITIONAL SUPPORT;

EID: 24344485181     PISSN: 10966781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation. 1999;99:2626-2632.
2. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients. Stroke. 2001;32: 2426-2432.
3. Marik P, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Int Care Med. 2004;30:748-756.
4. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
5. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003;31:359-366.
6. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA. 2003;290:2041-2047.
7. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 2003;78: 1471-1478.
8. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004;79:992-1000.
9. Umpierrez G, Isaacs SD, Bazargan N, You X, Thaler M, Kitabchi AE. Hyperglycemia: an independent marker of in hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-982.
10. Takala, J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341:785-792.
11. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total parenteral nutrition in surgical patients. New Engl J Med. 1991;325: 525-532.
12. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 2000;106:165-169.
13. Mizock B. Alterations in carbohydrate metabolism during stress: a review of the literature. Am J Med. 1995;98:75-84.
14. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest. 2004;114:1187-1195.
15. Pessin JE, Bell GI. Mammalian facultative glucose transporter family: Structure and molecular regulation. Annu Rev Physiol. 1992;54:911-930.
16. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin. 2001;17:107-124.
17. Mesotten D, Delhanty PJ, Vanderhoydonc F, et al. Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metab. 2002;87:5516-5523.
18. Montori VM, Bistrian BR, McMahon MM. Hyperglycemia in acutely ill patients. JAMA. 2002;288:2167-2169.
19. Shamoon H, Hendler R, Sherwin RS. Synergistic interactions among antiinsulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab. 1981;52:1235-1241.
20. McCowen K, Ling PR, Ciccarone A, et al. Sustained endotoxemia leads to marked down-regulation of early steps in the insulin-signaling cascade. Crit Care Med. 2001;29:839-846.
21. Aljada A, Ghanim H, Assian E, Dandona P. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism. 2002;51:487-491.
22. Senn JJ, Klover P, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278:13740-13746.
23. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277:42394-42398.
24. Mesotten D, Swinnen J, Vanderhoydonc F, Wouters PJ, Van den Berghe G. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab. 2004;89:219-226.
25. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360:219-223.
26. Fink MP. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin. 2001;17:219-237.
27. Pekala P, Marlow M, Heuvelman D, Connolly D. Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem. 1990;265: 18051-18054.
28. Quinn LA, McCumbee WD. Regulation of glucose transport by angiotensin II and glucose in cultured vascular smooth muscle cells. J Cell Physiol. 1998;177:94-102.
29. Shikhman AR, Brinson DC, Valbracht J, Lotz MK. Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol. 2001;167: 7001-7008.
30. Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet. 2005;365:53-59.
31. Siroen MP, van Leeuwen PA, Nijveldt RJ, Teerlink T, Wouters PJ, Van den Berghe G. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: A possible explanation of reduced morbidity and mortality? Crit Care Med. 2005; 33:504-510.
32. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage inhibitory factor. Nat Med. 2000;6:164-170.
33. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001; 86:3257-3265.
34. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G. Intensive insulin therapy exerts anti-inflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88:1082-1088.
35. Brown G, Dodek P. Intravenous insulin nomogram improves blood glucose control in the critically ill. Crit Care Med. 2001;29:1714-1719.
36. Clement S, Braithwaite SS, Magee MF, et al.; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553-591.
37. Nasraway SA Jr. Eliminating catheter-related blood stream infections: fairy tale or new reality? Crit Care Med. 2004;32:2150-2152.
38. Chiolero R, Revelly JP, Tappy L. Energy metabolism in sepsis and injury. Nutrition. 1997;13(suppl 9): 45S-51S.
39. Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab. 2001;15:533-551.
40. Tappy L, Berger M, Schwarz JM, et al. Hepatic and peripheral glucose metabolism in intensive care patients receiving continuous high- or low-carbohydrate enteral nutrition. JPEN J Parenter Enteral Nutr. 1999;23:260-267.
41. Richards JR, Drury JK. Energy exchanges and injury. Proc. Nutr. Soc. 1978;37:29-43.
42. Franz MJ, Bantle JP, Beebe CA, et al.; American Diabetes Association. Nutrition principles and recommendations in diabetes. Diabetes Care. 2004;27(suppl 1):S36-S46.
43. Esper D. Importance of blood glucose control in critically ill patients who have diabetes. Support Line. 2002;24:3-8.
44. McCowen KC Friel C, Sternberg J, et al. Hypocaloric total parenteral nutrition: effectiveness in prevention of hyperglycemia and infectious complications-a randomized clinical trial. Crit Care Med. 2000;28:3606-3611.
45. McMahon MM, Rizza RA. Nutrition support in hospitalized patients with diabetes mellitus. Mayo Clinic Proc. 1996;71:587-594.
46. American Society of Parenteral and Enteral Nutrition. Nutrition support in renal replacement therapies [audio teleconference]. May 6, 2004.
47. McCabe B, Frankel E, Wolfe J, eds. Handbook of Food-Drug Interactions. Boca Raton, FL: CRC Press; 2003.
48. Podel J, Hodelin-Wetzel R, Saha DC, Burns G. Glucose absorption in acute peritoneal dialysis. J Ren Nutr. 2000;10:93-97.
49. Manji S, Shikora S, McMahon M, Blackburn GL, Bistrian BR. Peritoneal dialysis for acute renal failure: overfeeding resulting from dextrose absorbed during dialysis. Crit Care Med. 1990;18:29-31.
50. Krajicek BJ, Kudva YC, Hurley HA. Potentially important contribution of dextrose used as diluent to hyperglycemia in hospitalized patients. Diabetes Care. 2005;28:981-982.
51. Hirsch IB, Paauw DS, Brunzell J. Inpatient management of adults with diabetes. Diabetes Care. 1995; 18:870-878.
52. Suchner U, Senftleben U, Eckart T, et al. Enteral versus parenteral nutrition: effects on gastrointestinal function and metabolism. Nutrition. 1996;12:13-22.
53. Schrezenmeir J. Rationale for specialized nutrition support for hyperglycemic patients. Clin Nutr. 1998;17:26-34.
54. Craig LD, Nicholson S, Silverstone FA, Kennedy RD. Use of reduced-carbohydrate, modified-fat enteral formula for improving metabolic control and clinical outcomes in long-term care residents with type 2 diabetes: results of a pilot trial. Nutrition. 1998;14:529-534.
55. del Carmen Crespillo M, Olveira G, Ruiz de Adana MS, et al. Metabolic effects on an enteral nutrition formula for diabetes: comparison with standard formulas in patients with type 1 diabetes. Clin Nutr. 2003;22:483-487.
56. Mesejo A, Acosta JA, Ortega C, et al. Comparison of a high-protein disease-specific enteral formula with a high-protein enteral formula in hyperglycemic critically ill patients. Clin Nutr. 2003;22:295-305.
57. Rosmarin DK, Wardlaw GM, Mirtallo J. Hyperglycemia associated with high, continuous infusion rates of total parenteral nutrition. Nutr Clin Pract. 1996; 11:151-156.